NTNikhil Kumar Tulsian

Nikhil Kumar Tulsian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikhil Kumar Tulsian has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human iPSC-derived motor neurons with TDP-43 nuclear loss present early ALS pathological phenotypes

    by Tze Khee Chan, Shahriar Niroomand, U-Ming Lim, Emelyne Teo, Nikhil Kumar Tulsian, Tayfun Tumkaya, Craig A. Parish, Vladimir Simov, Jia Ling Tiffany Yeo, Jing Wesley Leong, et al.

    Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disorder characterized by progressive loss of motor neurons and presents a critical need for effective treatments. To investigate the impact of TAR DNA-binding protein 43 (TDP-43) nuclear depletion in ALS, we established and characterized a human-induced pluripotent stem cell-derived motor neuron model carrying a mutation that disrupts TDP-43 nuclear localization. The model successfully recapitulates functional deficits observed in ALS patients, including impaired neurite outgrowth, reduced axonal regeneration, and neuronal hyperexcitability. Proteomic and metabolomic profiling revealed early mechanisms underlying ALS neuronal pathophysiology, involving altered oxidative stress and neurotransmitter release. TDP-43 nuclear depletion led to mis-splicing STMN2 and KCNQ2 , defects characteristic of TDP-43-associated disease. Notably, a splice-switching antisense oligonucleotide successfully restored normal STMN2 splicing and function, demonstrating that directly correcting splicing defects can rescue motor neurons. This work provides a comprehensive understanding of TDP-43 nuclear depletion in the context of ALS pathogenesis and offers potential targets for RNA-targeted therapeutic intervention, pointing towards the development of precision medicine approaches and early diagnostic markers for ALS.

  • Open Access

    Insights into the regulation of CHIP E3 ligase-mediated ubiquitination of neuronal protein BNIP-H

    by Srihari Shankar, Yaochen Liu, Nikhil Kumar Tulsian, Boon Chuan Low, Qingsong Lin, J Sivaraman

    BCL2/adenovirus E1B 19-kDa protein-interacting protein 2 homolog (BNIP-H or Caytaxin), pivotal adaptor protein that facilitates cerebellar cortex growth and synaptic transmission, is post-translationally modified to regulate neuronal function. This study reports the ubiquitination of BNIP-H by CHIP (Carboxyl terminus of Hsc70-Interacting Protein), a U-box containing E3 ligase that is also regulated via autoubiquitination. Specifically, it was observed that CHIP autoubiquitinated itself primarily at Lys23 and Lys31 in-vitro. Mutation of these residues show the autoubiquitination of successive lysines of CHIP. In total, nine lysines on CHIP were identified as the autoubiquitination sites, the collective mutation of which completely terminated its autoubiquitination. Additionally, CHIP-mediated ubiquitination of BNIP-H is completely inhibited when BNIP-H bears arginine mutations at four key lysine residues. Next, using hydrogen deuterium exchange mass spectrometry a model of a plausible mechanism was proposed. The model suggests transient N-terminal interactions between the CHIP and BNIP-H which allows for the swinging of U-Box domain of CHIP to ubiquitinate BNIP-H. Following complex dissociation, BNIP-H population is regulated via the ubiquitin-proteasome pathway. Collectively, these results aid in our understanding of CHIP-mediated BNIP-H ubiquitination and provide further insight into the roles of these proteins in neuritogenesis and neurotransmission.


  • Open Access

    Isoform-specific C-terminal phosphorylation drives autoinhibition of Casein kinase 1

    by Rachel L. Harold, Nikhil K. Tulsian, Rajesh Narasimamurthy, Noelle Yaitanes, Maria G. Ayala Hernandez, Hsiau-Wei Lee, Priya Crosby, Sarvind M. Tripathi, David M. Virshup, Carrie L. Partch

    Casein kinase 1δ (CK1δ) controls essential biological processes including circadian rhythms and wingless-related integration site (Wnt) signaling, but how its activity is regulated is not well understood. CK1δ is inhibited by autophosphorylation of its intrinsically disordered C-terminal tail. Two CK1 splice variants, δ1 and δ2, are known to have very different effects on circadian rhythms. These variants differ only in the last 16 residues of the tail, referred to as the extreme C termini (XCT), but with marked changes in potential phosphorylation sites. Here, we test whether the XCT of these variants have different effects in autoinhibition of the kinase. Using NMR and hydrogen/deuterium exchange mass spectrometry, we show that the δ1 XCT is preferentially phosphorylated by the kinase and the δ1 tail makes more extensive interactions across the kinase domain. Mutation of δ1-specific XCT phosphorylation sites increases kinase activity both in vitro and in cells and leads to changes in the circadian period, similar to what is reported in vivo. Mechanistically, loss of the phosphorylation sites in XCT disrupts tail interaction with the kinase domain. δ1 autoinhibition relies on conserved anion-binding sites around the CK1 active site, demonstrating a common mode of product inhibition of CK1δ. These findings demonstrate how a phosphorylation cycle controls the activity of this essential kinase.


  • Open Access

    Nutrient conditions influence allelopathic capabilities of Ludwigia adscendens and other tropical macrophytes against Microcystis aeruginosa

    by Darren Z. H. Sim, Maxine A. D. Mowe, Simon M. Mitrovic, Nikhil K. Tulsian, Ganesh S. Anand, Darren C. J. Yeo

    Macrophytes may release allelochemicals that suppress competing phytoplankton, although it is unclear how their effectiveness could be influenced by environmental nutrient conditions. To approach this, we conducted a series of bioassays against the bloom‐forming cyanobacterium Microcystis aeruginosa using extracts and exudates from potentially allelopathic macrophytes under varying nutrient conditions. We screened six different tropical macrophytes and identified antialgal effects in both extracts and exudates of Ludwigia adscendens, Persicaria barbata, Pontederia crassipes and Vallisneria spiralis. Growth assays indicated that extract inhibitory effectiveness decreased as nutrient concentration increased from 5% to 50% strength. Focusing on the potent antialgal extract of L. adscendens, we determined that its inhibitory effects were enhanced by specifically reducing the availability of either micronutrient or bicarbonate availability, indicating a role of these nutrients in protecting algal cells from allelochemicals. Bioactivity‐guided fractionation and ultra‐performance liquid chromatography – mass spectrometry analyses of L. adscendens extract indicated that ellagitannins were the major constituent of bioactive extract fractions, suggesting an antialgal mechanism common to other tannic compounds. Novel allelopathic alkaloids and terpenoid compounds also were described, although their mechanisms of action are unknown. Our findings provide evidence that the availability of carbon and micronutrients to cyanobacteria could influence the effects of macrophyte allelochemicals. This interaction between the nutrient environment and allelochemical sensitivity of cyanobacteria can be substantial, and studies or applications involving allelopathic interactions between macrophytes and phytoplankton should consider this.


  • Open Access

    Defining neutralization and allostery by antibodies against COVID-19 variants

    by Nikhil Kumar Tulsian, Raghuvamsi Venkata Palur, Xinlei Qian, Yue Gu, Bhuvaneshwari D/O Shunmuganathan, Firdaus Samsudin, Yee Hwa Wong, Jianqing Lin, Kiren Purushotorman, Mary McQueen Kozma, et al.

    The changing landscape of SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies. The functional activity of neutralizing antibodies is linked to their quaternary changes occurring as a result of antibody-Spike trimer interactions. Here, we reveal the conformational dynamics and allosteric perturbations linked to binding of novel human antibodies and the viral Spike protein. We identified epitope hotspots, and associated changes in Spike dynamics that distinguish weak, moderate and strong neutralizing antibodies. We show the impact of mutations in Wuhan-Hu-1, Delta, and Omicron variants on differences in the antibody-induced conformational changes in Spike and illustrate how these render certain antibodies ineffective. Antibodies with similar binding affinities may induce destabilizing or stabilizing allosteric effects on Spike, with implications for neutralization efficacy. Our results provide mechanistic insights into the functional modes and synergistic behavior of human antibodies against COVID-19 and may assist in designing effective antiviral strategies.


  • Structural and functional characterization of Aedes aegypti pupal cuticle protein that controls dengue virus infection

    by Qingqing Huang, Edem Gavor, Nikhil Kumar Tulsian, Jingsong Fan, Qingsong Lin, Yu Keung Mok, R. Manjunatha Kini, J. Sivaraman

    The pupal cuticle protein from Aedes aegypti (AaPC) inhibits dengue virus (DENV) infection; however, the underlying mechanism of this inhibition remains unknown. Here, we report that AaPC is an intrinsically disordered protein and interacts with domain I/II of the DENV envelope protein via residues Asp59, Asp61, Glu71, Asp73, Ser75, and Asp80. AaPC can directly bind to and cause the aggregation of DENV, which in turn blocks virus infection during the virus‐cell fusion stage. AaPC may also influence viral recognition and attachment by interacting with human immune receptors DC‐SIGN and CD4. These findings enhance our understanding of the role of AaPC in mitigating viral infection and suggest that AaPC is a potential target for developing inhibitors or antibodies to control dengue virus infection.


  • Open Access

    Isoform-specific C-terminal phosphorylation drives autoinhibition of Casein Kinase 1

    by Rachel L. Harold, Nikhil K. Tulsian, Rajesh Narasimamurthy, Noelle Yaitanes, Maria G. Ayala Hernandez, Hsiau-Wei Lee, Priya Crosby, Sarvind M. Tripathi, David M. Virshup, Carrie L. Partch

    Casein kinase 1 δ (CK1δ) controls essential biological processes including circadian rhythms and Wnt signaling, but how its activity is regulated is not well understood. CK1δ is inhibited by autophosphorylation of its intrinsically disordered C-terminal tail. Two CK1 splice variants, δ1 and δ2, are known to have very different effects on circadian rhythms. These variants differ only in the last 16 residues of the tail, referred to as the extreme C-termini (XCT), but with marked changes in potential phosphorylation sites. Here we test if the XCT of these variants have different effects in autoinhibition of the kinase. Using NMR and HDX-MS, we show that the δ1 XCT is preferentially phosphorylated by the kinase and the δ1 tail makes more extensive interactions across the kinase domain. Mutation of δ1-specific XCT phosphorylation sites increases kinase activity both in vitro and in cells and leads to changes in circadian period, similar to what is reported in vivo . Mechanistically, loss of the phosphorylation sites in XCT disrupts tail interaction with the kinase domain. δ1 autoinhibition relies on conserved anion binding sites around the CK1 active site, demonstrating a common mode of product inhibition of CK1δ. These findings demonstrate how a phosphorylation cycle controls the activity of this essential kinase. Significance: Subtle control of kinase activity is critical to physiologic modulation of multiple physiological processes including circadian rhythms. CK1δ and the closely related CK1ε regulate circadian rhythms by phosphorylation of PER2, but how kinase activity itself is controlled is not clear. Building on the prior observation that two splice isoforms of CK1δ regulate the clock differently, we show that the difference maps to three phosphorylation sites in the variably spliced region (XCT) that cause feedback inhibition of the kinase domain. More broadly, the data suggest a general model where CK1 activity on diverse substrates can be controlled by signaling pathways that alter tail phosphorylation. These inhibitory phosphorylation sites could also be targets for new therapeutic interventions.


  • Open Access

    Defining neutralization and allostery by antibodies against COVID-19 variants

    by Nikhil Tulsian, Palur Raghuvamsi, Xinlei Qian, Yue Gu, Bhuvaneshwari D/O Shunmuganathan, Firdaus Samsudin, Yee Hwa Wong, Jianqing Lin, Kiren Purushotorman, Mary Kozma, et al.

    The changing landscape of mutations in the SARS-CoV-2 Spike protein is linked to the emergence of variants, immune-escape and reduced efficacy of the existing repertoire of anti-viral antibodies. A major factor that contributes to the functional activity of the neutralizing antibodies are the intrinsic quaternary changes that occur as a result of antibody-Spike trimer interactions. In this study, we reveal the conformational dynamics and allosteric perturbations linked to binding of human monoclonal antibodies and the viral Spike protein. We identify epitope hotspots of known and novel antibodies, and associated changes in Spike dynamics that define weak, moderate and strong neutralizing antibodies. We show the impact of mutations in Wuhan, Delta, and Omicron variants of concern (VoCs) and differences observed in the antibody-induced conformational changes and illustrate how these render certain antibodies ineffective. Our comparative analyses of the antibody-footprints on Spike variants reveal how antibodies with similar binding affinities may induce destabilizing and stabilizing allosteric effects. These differences have important implications for neutralization efficacy and for developing new antibodies targeting emerging variants. Our results provide mechanistic insights into the functional modes and synergistic behavior of human antibodies against COVID-19, and provide a rationale to design effective antiviral strategies.

  • Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein

    by Lorena Zuzic, Firdaus Samsudin, Aishwary T. Shivgan, Palur V. Raghuvamsi, Jan K. Marzinek, Alister Boags, Conrado Pedebos, Nikhil K. Tulsian, Jim Warwicker, Paul MacAry, et al.


  • Mapping of molecular interactions between human E3 ligase TRIM69 and Dengue virus NS3 protease using hydrogen–deuterium exchange mass spectrometry

    by Tanaya Bagga, Nikhil Kumar Tulsian, Yu Keung Mok, R. Manjunatha Kini, J. Sivaraman

    Tripartite motif (TRIM) E3 ligases target specific substrates, including viral proteins, for proteasomal degradation, and are thus essential regulators of the innate antiviral response. TRIM69 ubiquitinates the non-structural NS3 protein of Dengue virus for its degradation by the host machinery. This antiviral strategy abrogates the immunosuppression mediated by the NS2B–NS3 protease complex. To understand how this host-driven antiviral response against Dengue virus, we sought to define the mode of interaction between human TRIM69 and Dengue NS2B–NS3 and the subsequent polyubiquitination of the protease by the E3 ligase. We show that NS2B–NS3Δpro is sufficient as a substrate for ubiquitination by TRIM69 using ELISA and in vitro assays. Using hydrogen–deuterium exchange mass spectrometry (HDXMS), we mapped the interface of the interaction between TRIM69 and NS2B–NS3Δpro, and propose a rationale for the binding and subsequent ubiquitination process. Furthermore, through sequence analysis, we showed that the regions targeted by TRIM69 on the DENV-2 NS3 protease (NS3Δpro) are well conserved across DENV serotypes and other flaviviruses, including Zika virus, West Nile virus, and Japanese encephalitis virus. Our results show the direct interactions of TRIM69 with viral proteins, provide mechanistic insights at a molecular level, and highlight the functional relevance of TRIM69 interacting with the Dengue viral protein. Collectively, our findings suggest that TRIM69 may act as a pan-antiflaviviral restriction factor.